Author

J. Schaletzky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Wehri· 5 shared X. Nguyenla· 3 shared C. Dugast-Darzacq· 2 shared E. Van Dis· 2 shared L. H. Yamashiro· 2 shared S. Stanley· 2 shared A. Jack· 1 shared A. K. Snyder· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

E. Wehri

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis

J. M. Hendricks, C. Doubravsky, E. Wehri, Z. Li, M. A. Roberts, K. Deol, M. Lange, I. Lasheras-Otero, S. J. Dixon, K. Bersuker, J. Schaletzky, J. A. Olzmann

This study identifies structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis, with FSEN1 showing potent on-target inhibition and synergy with ferroptosis inducers.

Cell Chemical Biology · Sep 1, 2023Peer-reviewedCancer Biology

The class XIV myosin of Toxoplasma gondii, TgMyoA, is druggable in an animal model of infection

A. Kelsen, R. S. Kent, A. K. Snyder, E. Wehri, S. J. Bishop, R. V. Stadler, C. Powell, B. Martorelli di Genova, P. K. Rompikuntal, M. J. Boulanger, D. M. Warshaw, N. J. Westwood, J. Schaletzky, G. E. Ward

This paper identifies KNX-002 as a specific inhibitor of TgMyoA, reducing parasite motility and disease progression in mice.

bioRxiv · Sep 9, 2022 · PreprintMicrobiology

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

S. B. Biering, E. Van Dis, E. Wehri, L. H. Yamashiro, X. Nguyenla, C. Dugast-Darzacq, T. G. Graham, J. R. Stroumza, G. R. Golovkine, A. W. Roberts, D. M. Fines, J. N. Spradlin, C. C. Ward, T. Bajaj, D. Dovala, , S. A. Stanley

This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.

bioRxiv · Dec 30, 2020Microbiology

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

X. Nguyenla, E. Wehri, E. Van Dis, S. Biering, L. H. Yamashiro, J. Stroumza, C. Dugast-Darzacq, T. Graham, S. Stanley, J. Schaletzky

This study identifies 20 approved drugs that synergize with remdesivir to inhibit SARS-CoV-2 replication in human lung cells, with HCV NS5A inhibitors showing the strongest effects.

bioRxiv · Sep 18, 2020Microbiology

SARS CoV-2 nucleocapsid protein forms condensates with viral genomic RNA

A. Jack, L. S. Ferro, M. J. Trnka, E. Wehri, A. Nadgir, K. Costa, J. Schaletzky, A. Yildiz, X. Nguyenla, S. Stanley

This study shows that SARS-CoV-2 nucleocapsid protein forms condensates with viral RNA in vitro and in cells, driven by hydrophobic and electrostatic interactions.

bioRxiv · Sep 14, 2020Biophysics